Clinical Trial Update: Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF [Phase 2]

View source ↗

Summary

Phase 2 trial of irinotecan plus brivanib in metastatic colorectal cancer with elevated plasma FGF was terminated; results posted but no positive pivotal outcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Colorectal Cancer

Drugs mentioned

• Brivanib (brivanib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-09-03